Добірка наукової літератури з теми "Conception de drogues par fragments"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Conception de drogues par fragments".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Conception de drogues par fragments"
Mustafa, Cecep. "La perspective judiciare sur la réhabilitation des drogues en Indonésie." Fiat Justisia: Jurnal Ilmu Hukum 14, no. 4 (July 28, 2020): 381. http://dx.doi.org/10.25041/fiatjustisia.v14no4.1952.
Повний текст джерелаMoysan-Lapointe, Héloïse. "La vérité chez Protagoras." Articles spéciaux 66, no. 3 (January 19, 2011): 529–45. http://dx.doi.org/10.7202/045337ar.
Повний текст джерелаCôté, Philippe-Benoit, Martin Blais, Céline Bellot, and Hélène Manseau. "Des expériences affectives et sexuelles en situation de rue1." Criminologie 46, no. 2 (December 13, 2013): 243–61. http://dx.doi.org/10.7202/1020995ar.
Повний текст джерелаCordero, Nestor Luis. "Les deux manières d’expliquer la réalité proposées par Parménide." Peitho. Examina Antiqua 13, no. 1 (December 23, 2022): 13–24. http://dx.doi.org/10.14746/pea.2022.1.1.
Повний текст джерелаBell, Kirsty. "Des ateliers et des arbres." Arborescences, no. 4 (November 20, 2014): 65–83. http://dx.doi.org/10.7202/1027432ar.
Повний текст джерелаGosselin, Katerine. "L’« art romanesque », du Mentir-vrai aux Incipit." Études littéraires 45, no. 1 (July 15, 2014): 91–102. http://dx.doi.org/10.7202/1025942ar.
Повний текст джерелаDumont, François. "La surface et son envers. Poésie et poétique chez Robert Melançon." Tangence, no. 113 (June 5, 2017): 45–61. http://dx.doi.org/10.7202/1040007ar.
Повний текст джерелаMadden, Brooke, Craig Kenneth Michaud, Tarah Edgar, and Jennifer Jones. "Wandering With/In the University of Alberta: Teaching Subjects & Place-based Truth & Reconciliation Education." Alberta Journal of Educational Research 66, no. 1 (February 19, 2020): 50–71. http://dx.doi.org/10.55016/ojs/ajer.v66i1.61704.
Повний текст джерелаVicens Pujol, Carlota. "Literatura francesa de viajes y códigod QR. Espacios culturales, espacios interculturales." Anales de Filología Francesa, no. 29 (November 24, 2021): 521–37. http://dx.doi.org/10.6018/analesff.481671.
Повний текст джерелаGillain, Nathalie. "François Bon, ou le désir de construire un livre « comme une ville »." Phantasia, 2020. http://dx.doi.org/10.25518/0774-7136.1158.
Повний текст джерелаДисертації з теми "Conception de drogues par fragments"
González-Alemán, Roy. "Computational fragment-based design of chemically modified oligonucleotides for selective protein inhibition : BACE1 as a case study." Electronic Thesis or Diss., université Paris-Saclay, 2023. http://www.theses.fr/2023UPASL149.
Повний текст джерелаFragment-based drug design (FBDD) has become an increasingly popular approach in ligand design, boasting numerous success stories within the drug discovery process. Despite some challenges relating to synthetic accessibility and ligand-design strategies, FBDD remains a promising method for addressing chemical space, molecular complexity, binding probability, and ligand efficiency. RNA therapeutics are rapidly expanding, undergoing a resurgence due to the several advantages of these molecules over traditional drugs and antibodies, including their small size, ease of synthesis, stability, and lack of immunogenicity. However, like many other drugs, off-target effects (where inhibitors designed for a specific molecule inadvertently inhibit others unintended) can hinder their usage. In this study, we introduce an in silico strategy for the fragment-based designing of a promising class of ligands: chemically modified oligonucleotides that exhibit potential selectivity for their intended targets. As a proof of concept, we employed the BACE1 enzyme, a well-established therapeutic target for Alzheimer's disease. The fragments library exploration was conducted through extensive docking simulations of mono-nucleotides using the Multiple Copy Simultaneous Search method, whose docking and screening power were rigorously assessed through a comprehensive benchmark of 121 nucleotide-protein complexes for the first time. An efficient nucleotide assembler was developed to link the best hits obtained in docking stages. Differential analysis of the best-scored oligonucleotides allowed us to find specific binding modes to BACE1 over BACE2. At a methodological level, we also propose substantial memory optimization of four widely employed clustering algorithms, which allow the identification of essential structural features for ligand-receptor binding, an integral part of any FBDD campaign
Chung, Florence. "Conception par fragments de ligands de l'ARNtLys3." Paris 5, 2007. http://www.theses.fr/2007PA05P616.
Повний текст джерелаRetroviral replication of HIV-1 requires host-encoded tRNALys3 for priming reverse transcription. In order to inhibit transcription, the strategy aims to prevent recognition between tRNALys3 and viral RNA by targeting tRNALys3 with small molecules. TRNALys3 ligands have been synthesized by a fragment-based approach. Interactions of these ligands to tRNA were studied by NMR and fluorescence spectroscopy. Development of these ligands was made from two molecules identified in a NMR primary screening: kynuramine and diaminocyclopentanol. These fragments bind with millimolar affinity to different sites within the tRNA. Simple structural changes were first made on kynuramine. The fragments were then linked by aminoester and triazole groups. Finally, diaminocyclopentanol dimers were developed by incorporating aromatic groups
Maillard, Ludovic. "Vers la conception d'inhibiteurs de la glucosamine-6P synthase par assemblage de fragments : sélection des fragments assistée par le substrat." Paris 11, 2006. http://www.theses.fr/2006PA114812.
Повний текст джерелаA fragment-based approach has been considered to design new inhibitors of glucosamine-6P synthase (Glms). This enzyme catalyzes the formation of glucosamine-6P from fructose-6P. Identification of low affinity ligands as well as elucidation of their binding site is often a limiting step. An alternative strategy where the fragments are tethered to the substrate to increase their affinity for the enzyme and to address them to the protein binding-site is proposed. Fructose-6P was used as a platform to target the components of an alkoxyamine library towards the active site of the enzyme via oxime formation. Fragments able to interact with Glms were selected from in-vitro enzymatic activity assay. The overall process leading to the identification of a first series of fragments is presented: development of a parallel solid phase synthesis of alcoxyamines, preparation of fructose-6P oxime ether library, development of a new enzymatic assay for Glms by mass spectrometry and results of screening
Tran, Ngoc Chau. "Conception, synthèse et développement de nouveaux composés antituberculeux selon une approche par fragments." Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S013/document.
Повний текст джерелаIn 1993, the World Health Organization (WHO) declared Tuberculosis (TB) as a global public health emergency. Over 20 years later, this infectious disease caused by Mycobacterium tuberculosis, remains a major public health problem. Despite the significant progress in the fight against TB worldwide, WHO estimates that 9 million people contracted the disease in 2013 and 1.5 million died in that year. In addition, the emergence of multidrug-resistant tuberculosis (MDR-TB) requires the development of new tools and new therapeutic strategies. Recently, two new compounds, bedaquiline and delamanid were approved in MDR-TB treatment in order to strengthen the actual MDR-TB chemotherapy. Nevertheless, there is always the possibility that the tubercle bacillus can quickly develop resistance related to the mechanism of action of these new drugs. Therefore, the actual therapeutic arsenal must be strengthened. This thesis is based on the discovery and optimization of new anti-TB compounds starting from the screening of small molecules called fragments.The first part of this thesis is the continuation of the research project which was started during the thesis of Baptiste Villemagne. This work aims to develop compounds that can boost the activity of ethionamide, a second-line drug used to treat MDR-TB. The transcriptional repressor EthR has been validated as a key element in the bioactivation of ethionamide. EthR inhibitors were identified using a fragment-based approach and were optimized to potentiate the activity of ethionamide in vitro. However, the low microsomal stability of the lead compound has limited its use in vivo. The metabolism study of the lead compound and key structural modifications allowed a development of new potent EthR inhibitors having acceptable pharmacokinetic and physico-chemical properties for in vivo testing.The second part of this thesis focused on the synthesis of MabA inhibitors. MabA is a mycobacterial β-ketoacyl-ACP reductase involved in the synthesis of long-chain fatty acids, precursors of mycolic acids, which are major constituents of the mycobacterial cell wall. This enzyme has been shown to be essential for the survival of the bacteria but until now no inhibitor has been identified. Screening of a library of fragment molecules on MabA was performed via two different assays (affinity assay using TSA and an enzymatic assay). The identified hits were re-synthesized and tested in a functionnal assay. The optimization steps to improve the activity of the hits are also described. Compounds with activity in the micromolar range were discovered.In the third part, a design and synthesis of new fragments is described. The aim of this project is to build a collection of original fragments showing a 3D-structure scaffold amenable for rapid derivatization. The fragments that contain an original isoxazoline motif were synthesized from alkenes and aldoxime as starting building-blocks by using 1,3-dipolar cycloaddition. The conformational analysis of these structures has shown that they were, as expected, able to deploy substituents in the 3D space. The experimental solubility of these fragments was also measured and the results demonstrated that these molecules are suitable for the screening against new biological targets to help kick-start hit discovery program
URIEL, ARIAS MARIA CLARA. "C-glycosides antitumoraux. Conception, synthese, et etude structurale. Application au ciblage des drogues par preparation de conjugues lipidiques et glycosidiques." Paris 6, 1995. http://www.theses.fr/1995PA066222.
Повний текст джерелаPrevet, Hugues. "Conception et synthèse de molécules à visée anti-infectieuse selon deux stratégies : le criblage à haut débit et l’approche par fragments." Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S037/document.
Повний текст джерелаThe discovery of drug candidates is based on the identification of hits with appropriated physico-chemical properties for further development. High throughput screening and fragment-based drug discovery approaches are two strategies commonly used for this identification. These strategies were applied during my PhD research work for identifying not only new modulators of the CD81/CLDN-1 complex to prevent entry of the Hepatitis C virus (HCV) into hepatocytes but also inhibitors of the mycobacterial transcriptional repressor, called EthR2, to boost ethionamide antibacterial activity against resistant strains of M. tuberculosis.Firstly, a high throughput screening assay was developed to identify molecules bearing a thieno[2,3-c]pyrazole scaffold that modulate the CD81/CLDN-1 complex. The structure-activity relationships allowed us to design and synthesize one non-toxic compound that inhibits viral entry with an IC50 in the submicromolar range. This best analog will be used as pharmacological tool to understand the molecular mechanism involving the CD81/CLDN-1 interaction during virus entry.Secondary, we worked on the design and synthesis of a new generation of fragments called privileged fragments. We focused our interest on the 1,4-benzodiazepine-2,5-dione and spirohydantoin scaffolds and using microwave-assisted conditions 44 original privileged fragments have been synthesized. To further illustrate the potential of our privileged fragments, a virtual focused library has been generated and screened in silico on MDM2 protein. The in vitro evaluation of the identified hits will allow us to validate our approach and to show the potential of our privileged fragments for the discovery of new hits against protein-protein interactions.Finally, inhibitors of a new mycobacterial transcriptional repressor involved in the boosting of ethionamide activity have been developed. Screening of 960 fragments allowed us to identify a hit bearing a tropinone scaffold which was cocrystallized with EthR2. A rational design from this cocrystal structure led rapidly to more potent ligands
Villemagne, Baptiste. "Conception, synthèse et dévelopement d'inhibiteurs du répresseur transcriptionnel mycobactérien ETHR selon une approche par fragments. Une nouvelle approche dans la lutte contre la tuberculose." Thesis, Lille 2, 2012. http://www.theses.fr/2012LIL2S052/document.
Повний текст джерелаTuberculosis (TB) remains the leading cause of death due to a single infective agent with more than 1.5 million people killed each year. In 2011, the world health organization (WHO) estimated that one third of the world’s population is infected with Mycobacterium tuberculosis, the pathogen responsible for the disease. This phenomenon may be due to an explosive escalation of TB incidence that occurred in the 1980s due to the emergence of both resistant strains and HIV epidemic.In 2000, EthR, a mycobacterial transcriptional repressor, was identified as a key modulator of ethionamide (ETH) bioactivation. ETH is one of the main second-line drugs used to treat drug resistant strains. In 2009, it was shown that co-administration of ETH and drug-like inhibitors of EthR was able to boost ETH activity threefold in a mouse-model of TB-infection, thus validating the target for a new therapeutic strategy.This work deals with the discovery and optimisation of new EthR inhibitors, based on a small molecule, called a “fragment”, co-crystallized with the protein. We combined in silico screening, in vitro evaluation of the hit compounds, study of co-crystal structures and medicinal chemistry to develop three complementary approaches called “fragment growing”, “fragment merging” and “fragment linking” that led to the discovery of very potent inhibitors. Based on these results, we are currently selecting a potential candidate for new in vivo experiments
Lepron, Marco. "Conception de ligands allostériques du sous-type α5 des récepteurs nicotiniques à l'acétylcholine". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS584.
Повний текст джерелаNicotinic acetylcholine receptors (nAChRs) are transmembrane proteins belonging to the superfamily of pentameric ligand-gated ion channels (pLGICs). They mediate neuronal synaptic transmission and modulation and are currently a therapeutic target for a wide range of diseases including Alzheimer disease, schizophrenia, and tobacco addiction. The most abundant brain nAChRs are the homomeric α7 and heteromeric α4β2 subtypes. The minor subpopulation of the α5(α4β2)2 receptors containing the “accessory” α5 subunit raised recently much interest since its mutation in human population is strongly linked to both smoking addiction and lung cancer. Thus, the α5(α4β2)2 subtype constitutes a promising and specific target for the development of anti-smoking drugs through the design of α5/α4 interface-specific ligands that will act as Positive or Negative Allosteric Modulator (PAM/NAM).Albeit this α5-containing subtype remains orphan up to now, a series of natural alkaloids were randomly screened on AChBP-5/4, a surrogate of the extracellular domain of nAChRs in which the α5/α4 interface has been engineered by specific molecular mutations. A few ligands presenting an affinity for this mutant within a micromolar range were identified. Among them, (−)-lobeline is the most promising “hit”.Besides this screening approach of whole molecules, we initiated a program of Fragment-Based Drug Discovery (FBDD) of allosteric modulators. An in-house fragments library was built thanks to the deconstruction of more than 300 cholinergic ligands and was refined into 1300 fragments possessing the essential pharmacophoric elements and matching with the rule of three. This library is currently evaluated by in silico docking experiments and ligand-based NMR assays.In parallel, inspired by the lobeline structural features and fragments ubiquitously found in cholinergic alkaloids, we developed a strategy of rational design of new ligands or prototypes based on molecular hybridization. In this context, we shaped new synthetic pathways including diastereoselective intramolecular reduction from amine-borane complexes and enantioselective functionalization of masked iminium
Teyssier, Cécile. "Spectrométrie de masse COINTOF : Conception et d'un analyseur à temps de vol et développement de la méthode d'analyse." Phd thesis, Université Claude Bernard - Lyon I, 2012. http://tel.archives-ouvertes.fr/tel-00744850.
Повний текст джерелаHoffer, Laurent. "Développement et validation du logiciel S4MPLE : application au docking moléculaire et à l'optimisation de fragments assistée par ordinateur dans le cadre du fragment-based drug design." Phd thesis, Université de Strasbourg, 2013. http://tel.archives-ouvertes.fr/tel-00874644.
Повний текст джерелаЧастини книг з теми "Conception de drogues par fragments"
Zaitseva, Natalia, and Anastassia Ivkina. "Thésaurus dans l’enseignement du français professionnel." In Quelles compétences en langues, littératures et cultures étrangères ?, 69–80. Editions des archives contemporaines, 2021. http://dx.doi.org/10.17184/eac.3890.
Повний текст джерела